Forty-day cytisine regimen
13 evidence topics · 2 sources
Objective
Regimen objective
Location and study date
Study period and country
| Characteristic | Quoted value |
|---|---|
| Observation period | “2015–2021” |
| Country | “Italy” |
Study design
Nonrandomized allocation
Eligibility criteria
Treatment
Compared treatment durations
| Characteristic | Quoted value |
|---|---|
| Cytisine | “40 days” |
| Varenicline | “12 weeks” |
| Nicotine replacement therapy | “eight weeks” |
Study outcomes
Rationale for using biochemically confirmed smoking abstinence as a study endpoint
Abstinence assessment
| Characteristic | Quoted value |
|---|---|
| Follow-up interval | “6 months” |
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Continuous-variable comparison
Results
Participant disposition
No evidence found.
Baseline characteristics
Cytisine group at baseline
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “52.5” |
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Allocation was not randomized, and there was no placebo group or direct comparison with the standard 25-day cytisine regimen. The observed differences cannot establish that extending treatment to 40 days caused improved outcomes.